DigestRedComo funciona
Red
/
Empresas
AC
No verificado

ACADIA Pharmaceuticals Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosPsiquiatríaSalud

60 Comunicados de prensa

Ver todos los comunicados de prensa
20/11/2025
Eventos
Web y redes sociales
Ciencia
Biotecnología
Farmacéutica
Salud
Psiquiatría
Medicina - Varios
Acadia Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference
Fuente
ACADIA Pharmaceuticals Inc.
Editor
Business Wire
1.00
0
05/11/2025
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Web y redes sociales
Telefonía
Mercado de valores
Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview
Fuente
ACADIA Pharmaceuticals Inc.
Editor
Business Wire
1.00
0
28/10/2025
Biotecnología
Farmacéutica
Salud
Eventos
Web y redes sociales
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
Fuente
ACADIA Pharmaceuticals Inc.
Editor
Business Wire
1.00
0
15/10/2025
Psiquiatría
Salud
Medicina - Varios
Farmacéutica
Biotecnología
Web y redes sociales
Telefonía
Finanzas
Mercado de valores
Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025
Fuente
ACADIA Pharmaceuticals Inc.
Editor
Business Wire
1.00
0
02/10/2025
Ciencia
Biotecnología
Farmacéutica
Salud
Psiquiatría
Medicina - Varios
Eventos
Industria
Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®
Fuente
ACADIA Pharmaceuticals Inc.
Editor
Business Wire
1.00
0
24/09/2025
Industria
Psiquiatría
Salud
Medicina - Varios
Farmacéutica
Biotecnología
Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint
Fuente
ACADIA Pharmaceuticals Inc.
Editor
Business Wire
1.00
0
12/09/2025
Ciencia
Biotecnología
Farmacéutica
Salud
Psiquiatría
Medicina - Varios
Industria
Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology
Fuente
ACADIA Pharmaceuticals Inc.
Editor
Business Wire
1.00
0
08/09/2025
Psiquiatría
Salud
Ciencia
Farmacéutica
Biotecnología
Mercado laboral
Finanzas
Mercado de valores
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fuente
ACADIA Pharmaceuticals Inc.
Editor
Business Wire
1.00
0
26/08/2025
Ciencia
Biotecnología
Farmacéutica
Salud
Psiquiatría
Medicina - Varios
Eventos
Web y redes sociales
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
Fuente
ACADIA Pharmaceuticals Inc.
Editor
Business Wire
1.00
0
25/08/2025
Psiquiatría
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Mercado laboral
Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer
Fuente
ACADIA Pharmaceuticals Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0